Management of Erythromelalgia
Start with topical therapies (4-week trials) combined with aspirin 325 mg daily (1-month trial) as first-line treatment, after evaluating for and treating any underlying causes, particularly myeloproliferative disorders. 1
Initial Evaluation and Lifestyle Management
Before initiating pharmacologic treatment, evaluate for secondary causes:
- Screen for myeloproliferative diseases (essential thrombocytosis, polycythemia vera) - aspirin is dramatically effective in these cases, often within days 1
- Check for neuropathy, autoimmune conditions, and other underlying associations
- Treat identified causes directly
Critical safety counseling: Patients must avoid prolonged ice or water immersion, which causes tissue damage, ulcerations, and potential amputation. Limit cooling to 10 minutes maximum, 4 times daily. Fans can cause windburn-equivalent injury. 1 This is essential because patients with erythromelalgia have significantly increased morbidity, mortality, and suicide risk compared to the general population. 1
First-Line Pharmacologic Treatment
Topical Therapies (Trial each for 4 weeks)
For pain control:
- Lidocaine patches 4-5%: Apply up to 3 patches to affected areas for 12-24 hours. More effective than cream/ointment formulations due to gradual delivery. 1
- Compounded amitriptyline 1-2% with ketamine 0.5%: Apply up to 3 times daily. In case series, 75% of patients improved. Can increase ketamine concentration to 5% if initial trial ineffective. 1
For redness (which often reduces pain):
- Compounded midodrine 0.2% in Vanicream: Apply 3 times daily. This α1-agonist vasoconstrictor showed improvement in a 12-patient case series. 1
- Alternative options: oxymetazoline 0.05%, brimonidine tartrate 0.33% (both FDA-approved for rosacea), or timolol maleate 0.5%. Warn about rebound erythema risk. 1
Systemic First-Line: Aspirin
Aspirin 325 mg orally daily for minimum 1 month 1
- Mechanism: inhibits prostaglandin synthesis and platelet aggregation
- Especially effective in myeloproliferative-associated erythromelalgia - dramatic improvement within days
- In case series, 50% of patients reported benefit
- Low cost, relatively safe profile makes this mandatory first-line unless contraindicated
For aspirin allergy: Consider other NSAIDs (ibuprofen, indomethacin, naproxen, piroxicam) - nearly half showed benefit in studies 1
Second-Line Treatment (Add to above if inadequate response)
Trial each systemic therapy for 3-4 months before switching: 1
Step 1 (evidence-based preferred):
- Gabapentin: Start 300 mg at bedtime, titrate up to 2400 mg daily divided into 3 doses, OR
- Pregabalin: 75-300 mg every 12 hours 1
- Alternative consideration: Venlafaxine up to 75 mg daily 1
Step 2 (if Step 1 inadequate):
- Selective serotonin reuptake inhibitors (sertraline preferred over fluoxetine), OR
- Amitriptyline (systemic), OR
- Sodium channel blockers: Mexiletine or carbamazepine 1
The rationale for sodium channel blockers is particularly strong in inherited/primary erythromelalgia with SCN9A mutations (gain-of-function Nav1.7 sodium channels), though these mutations are present in only ~5% of cases. 1
Special Circumstances
For sudden onset, clear precipitant, or disease duration <1 year: Consider systemic corticosteroids to prevent irreversible nociceptive remodeling and central sensitization:
- Methylprednisolone 1000 mg IV daily for 5 days (total 5000 mg), OR
- Prednisone ≥40 mg daily for 5 days (total ≥200 mg) 1
Additional options with limited evidence:
- Antihistamines (cyproheptadine, chlorpheniramine, diphenhydramine, cetirizine)
- Beta blockers (atenolol, nadolol, propranolol, timolol)
- High-dose magnesium (oral or IV 2g every 2-3 weeks)
- IV immunoglobulin for underlying autoimmune disease 1
Third-Line Treatment
Refer to comprehensive pain rehabilitation center for severe, refractory, or disabling cases. 1 This multidisciplinary approach is critical given the significant quality of life impairment and suicide risk in this population.
Key Clinical Pitfalls
- Do not delay aspirin trial - it's safe, cheap, and dramatically effective in myeloproliferative cases
- Screen for myeloproliferative disease - these patients have a distinct treatment response
- Give adequate trial durations: 4 weeks for topicals, 1 month for aspirin, 3-4 months for other systemic agents
- Prevent cooling-related injuries - this causes significant morbidity including amputation
- Don't assume capsaicin will help - despite theoretical benefit, clinical experience shows it's often ineffective 1
- Evidence quality is generally low for most interventions except aspirin in myeloproliferative disease (moderate certainty) 2
The 2023 Mayo Clinic Proceedings guideline 1 represents the most comprehensive and recent expert consensus on this challenging condition, emphasizing a stepwise algorithmic approach prioritized by evidence quality and safety profile.